Zydus, Indian pharmaceutical company on Wednesday states that its plasmid DNA coronavirus vaccine; ZyCoV-aD is now in its phase to start human trials to the healthy patient for its first and second phase to check for its potential. And hence are to conduct the test to over 1000 subjects across the nation.
From the statement released from Zydus, “ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies”. “Further, no vector response and with the absence of any infectious agent, the platform provides ease of manufacturing the vaccine with minimal biosafety requirements (BSL-1q),” they added.
Clinical trials and analysis all over the country are now at a race as the country recently goes up to the third most hit Covid-19 nation. The country now records unto 9 lakh cases with 63.02% recovery rate.
Also read these posts:
India’s first Covid-19 vaccine COVAXIN gets approval for human trials